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Case presentation
A 17-year-old white female was well until 3 weeks prior to admission
to another hospital, when she had noted erythema about her face after
one day at the beach but before she had spent any time sunbathing. She
had substantial sun exposure for the next 2 days but became nauseated
and febrile and remained indoors thereafter. Nevertheless, she devel-
oped pleurisy without a cough and lost 5 pounds. The facial erythema
persisted, as did the nausea. Two weeks prior to admission, she
developed a sore throat and diffuse myalgia. A throat culture was
negative for group-A streptococci. One week before admission, the
patient noted arthralgia in the knees, wrists, and metacarpophalangeal
and proximal interphalangeal joints of the hands; she noted increased
hair on her brush and pillow. The facial erythema and a low-grade fever
persisted. Fatigue became a prominent symptom.
Physical examination revealed a well-developed female of average
height and weight. She looked ill. The hair was slightly thin, and a
butterfly rash was present. One nasal and several oral ulcers were
present. There was minimal shotty cervical and axillary lymphadenop-
athy. The thyroid was normal. Heart rate was regular at 104 beats/mm.
The lungs were normal. The abdomen was unremarkable. There was no
costovertebral angle tenderness. The joints appeared normal but the
knees, wrists, and finger joints were tender. No edema was present.
Laboratory results were: white blood cell count, 7400/mm3 with 78%
polys, 9% bands, 10% lymphocytes, 2% monocytes, and 1% eosino-
phils; hemoglobin, 11.4 g/dl; erythrocyte sedimentation rate, 46 mm/hr
(Westergren); a positive LE cell test; and normal chemistries except for
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an SGOT and SGPT that each were twice the upper limit of normal.
Specifically, the serum creatinine was 0.7 mg/dl and the BUN was 18
mg/dl. A test for antinuclear antibodies was strongly positive with a
diffuse pattern at 1:2048. A test for rheumatoid factor was positive at a
titer of 1:320. The gamma globulins were diffusely elevated at 1.8 times
the upper limit of normal. Urinalysis showed 12 red blood cells and 6
white blood cells/high-power field. There were occasional coarse gran-
ular and fine granular casts. The urine was sterile. A 24-hour urine
collection contained 1.7 g of protein; a second collection contained 2.4
g of protein. Creatinine clearance was normal.
The patient had been taking aspirin prior to her hospitalization and
continued to do so, but she remained febrile at 101°F. Nausea and
anorexia were mild but persistent.
The patient was treated with prednisone, 20 mg/day, which produced
a prompt defervescence and relief of all of her symptoms. Within 3 days
she felt well. A radiograph of her abdomen showed kidneys of normal
or slightly large size. The family insisted that she be discharged from the
hospital.
One year later, the patient was again hospitalized. She had done well
for 8 months after discharge. Urinalyses became normal while she was
taking the 20 mg/day of prednisone, although low-grade proteinuna (0.5
g/24 hours) did persist. In the past few months, pleurisy, arthralgia, and
fatigue had increased, and in the past month ankle edema occurred. In
the last month, urinalyses showed 80 red blood cells/high-power field,
occasional red cell casts, and many granular casts; urine protein
excretion had increased to 4.8 g/day. The prednisone dose, which had
been tapered to 10 mg every other day 4 months previously, was raised
to 20mg/day 3 months previously and to 80 mg/day 2 weeks previously.
This high dose relieved all the symptoms except for the edema. Physical
examination at this time was normal, with the exception of 2 + pitting
ankle edema.
The patient was treated with plasmapheresis and 3 days of methyl-
prednisolone, I g/M2 body surface area. The serum creatinine was 1.6
mg/dl. A renal biopsy showed diffuse proliferative glomerulonephritis
with focal areas of necrosis and mild interstitial infiltration, but no
glomerular hyalinization or interstitial scarring. Subendothelial deposits
were apparent on electron microscopy. The patient then wanted to
leave the hospital. She was treated with high doses of corticosteroids
for 3 months; the regimen then was tapered. The urinalysis returned
toward normal with only 1 to 5 red blood cells/high-power field, and
proteinuria decreased to 1.2 g/day. The edema resolved, and the serum
creatinine was 1.1 mg/dl.
Three years later, at age 21, the patient presented in the third month
of pregnancy with ankle edema. Urinalysis revealed 50 red blood
cells/high-power field, and a 24—hour urine collection contained 5.1 g of
protein. The serum creatinine was 1.4 mg/dl and the BUN was 36 mg/dl.
She was hypertensive for the first time, having a blood pressure of
156/98 mm Hg.
Before a decision regarding a therapeutic abortion could be reached,
the patient had a spontaneous abortion. She then was treated with high
doses of prednisone and antihypertensive medications, and her blood
pressure fell to 110/74 mm Hg; the urinalysis gradually became normal.
The patient continued to have low-grade proteinuria of about 1 g/day.
She was anxious to avoid taking cyclophosphamide, as she wanted to
become pregnant in the future. Nevertheless, as the steroids were
tapered, the complement began to fall from nearly normal levels, and
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the anti-DNA titer, which had been high with each renal flare, began to
rise. The creatinine was 1.2 mg/dl.
The patient was advised to increase the dose of prednisone from 20
mg/day to 60 mg/day. Because she didn't like the side effects of the
steroid (weight gain, striae, etc.) she did not change the dose, Three
months later she presented with anasarca. A second renal biopsy
disclosed severe membranoproliferative glomerulonephritis with necro-
sis, much segmental or global glomerular hyalinization, and substantial
interstitial and periglomerular fibrosis. After a difficult negotiation
period, the patient finally agreed to treatment with boluses of cyclo-
phosphamide, I g/M2 monthly for one year. This treatment stabilized
the disease process; the urinalysis became normal and 24-hour urine
protein excretion fell to within normal limits, hut the serum ereatinine
was 1.8 mg/dl and hypertension required continued medication. The
patient wants to become pregnant.
Discussion
DR. ALFRED D. STEINBERG (Medical Director, United States
Public Health Service, and Chief, Cellular Immunology Sec-
tion, Arthritis and Rheumatism Branch, National Institute of
Arthrittc, Diabetes, and Digestive and Kidney Diseases, Na-
tional Institutes of Health, Bethesda, Maryland):
"The greater the ignorance the greater the dogmatism."
Sir William Osler [1]
Systemic lupus erythematosus (SLE) is a multisystem dis-
ease characterized by the production of a variety of autoanti-
bodies and by immune-mediated inflammation. The inflamma-
tory process may spare the major organs of the body or, in some
eases, involve vital organs such as the brain or kidney. As a
result of this wide clinical variability, the treatment of a given
patient with SLE should depend on the extent and severity of
the inflammatory process in that individual.
There is no known cure for SLE. Treatment therefore is
directed at relieving symptoms as well as preventing progres-
sion of the disease. Because many of the drugs used for the
latter purpose have substantial toxicities, one should try to
balance the potential risks of therapy with the potential bene-
fits, Obviously, the more severe the disease process, the more
acceptable the risks of vigorous treatment.
Consideration of the therapy of renal disease in patients with
SLE can be approached from many perspectives: historic,
histologic, clinical, serologic, and prognostic. In determining
therapy of renal disease in a patient with SLE, one also should
consider other individual factors: age, gender, psychologie
makeup (including hopes and fears), family, social situation,
extrarenal SLE, and other medical conditions [2].
Historic perspective
An appreciation of the current controversies in the diagnosis
and management of renal disease in patients with SLE is
incomplete without a sound historic perspective. The percep-
tion of SLE and renal disease in SLE has evolved substantially
in this century. Without an understanding of this evolution, it is
often difficult to make sense of apparent chaos in the literature:
survival with or without renal disease differs markedly in
different studies, as do histologic classifications of renal disease
and prognostic indicators. Further, a given therapy is deemed
beneficial in one paper and useless in another.
The term lupus, derived from the Latin for wolf, denoted
invasive and destructive facial ulcerations that sometimes were
thought to be a form of cancer. Because lupus originally
referred to a group of skin diseases, much of the early literature
is dermatologic; what we now know as discoid lupus and
systemic lupus erythematosus were admixed with tuberculosis,
psoriasis, and many other disorders. The term erytheme cen-
trifuge was introduced in 1833 [31 and was changed by
Cazenave around 1852 to lupus erythemateaux [4]. A butterfly
facial rash was described with SLE in 1845 [51. A major
advance occurred when Hebra and Kaposi distinguished be-
tween discoid lupus and the systemic form of the disease [61.
They pointed out that the systemic form, which could give rise
to fever, prostration, disturbed consciousness leading to coma,
and pleurisy, often led to death. Between 1895 and 1903, Osler
expanded on the visceral complications of SLE by noting
associated arthritis, endocarditis, pericarditis, gastrointestinal
crises, hemorrhage, various central nervous system manifesta-
tions, and, notably, nephritis [7, 8]. Moreover, he pointed out
that the visceral lesions could occur in the absence of the skin
disease. Similar descriptions came from Vienna [9].
Chronic glomerulonephritis was described in 4 patients with
SLE as early as 1922 [101. In 1935 so-called "wire loop" lesions
were described at postmortem examination in 13 of 23 patients
with SLE and were considered characteristic of the disease
[11]. Klemperer and colleagues introduced the term diffuse
collagen disease in 1941 [121; 4 years earlier, however, Keil had
pointed out that discoid lupus, which had been differentiated
from the systemic disorder in 1875 [61, could progress to the
disseminated disorder [131.
In the 1920s and 1930s, diagnostic findings for SLE included
a false-positive test for syphilis [141, hematoxylin-staining bod-
ies [15, 16], cytoid bodies in the eye [171, wire-loop lesions in
the kidney [11], onion-ring lesions of the splenic arteries [18],
and Libman-Sacks endocarditis [18, 191. Unfortunately most of
these "diagnostic" findings became evident only at autopsy.
Hargraves and colleagues announced in 1948 the discovery of
the LE cell [201, and this discovery prompted studies into the
factors responsible for the phenomenon. These studies culmi-
nated in the discovery of antinuclear antibodies [21—26], which,
with the development of fluorescence microscopy, dramatically
increased the ability to diagnose the disease during life. In
addition to its use in the identification of serum antinuclear
antibodies, fluorescence microscopy was applied to the analysis
of renal deposits. Mellors et al discovered that the deposits in
the glomerular capillary loops included gamma globulins [27].
This finding was extended to the demonstration of preferential
deposition of gamma globulins [23, 281 and also of complement
[29j. Freedman and Markowitz demonstrated that gamma glob-
ulin eluted from glomeruli reacted with nuclei [301. These
studies firmly placed SLE in the category of autoimmune
diseases. Subsequently, antibodies to RNA [31], SS-A or Ro
[321, retroviruses 133], hepatitis B virus [34], complement
components [35, 361 and fibrin and fibrinogen [37, 38], as well as
DNA [39, 401 have been demonstrated in kidneys of patients
with SLE.
Therapy for patients with SLE was grossly inadequate until
1949, when corticosteroids were introduced into clinical prac-
tice [41—46] and nitrogen mustard was given to patients with
renal disease [47]. But many years passed before adequate
antibiotic therapy was widely available, good antihypertensive
drugs were introduced, fluid and electrolyte problems were well
managed, and critical care medicine was advanced. The discov-
ery of new serologic tests in the late 1940s and in the 1950s led
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to an increase in the number of patients with SLE being
diagnosed during life. Further medical advances in the 1950s
and 1960s led to a marked increase in the survival rates for
patients with SLE, especially those with substantial renal
involvement.
Changes in perceptions about SLE
In the first part of this century, SLE was usually diagnosed
only after death [12, 48]. Subsequently, only severe cases of
SLE were diagnosed during the patient's life [49, 50]. The
disease was diagnosed more often during the 1960s, and milder
forms were recognized more readily. Nevertheless, lupus was
still feared almost as much as cancer. Physicians frequently told
patients' relatives that the diagnosis was SLE but withheld the
information from patients. With the recognition of increasingly
large numbers of mild cases, and the increase in mean survival
of patients with SLE, it became easier to give or receive a
diagnosis of SLE. Local support groups developed, a national
foundation grew, and even a national lupus week was declared.
Why has our perception of SLE changed over the past half
century? The disease probably has not changed very much,
although our diagnostic and therapeutic abilities have. Prior to
the advent of modern medicine, when a disease was diagnosed
according to pathologic criteria, it tended to be diagnosed
primarily at the autopsy table. With the availability of the LE
cell test in 1948 [20], tests for antinuclear and anti-DNA
antibodies [21—26, 51—56], and increased clinical awareness,
SLE became more and more readily diagnosed during life. In
my formative years in medicine, the average patient with
extrarenal SLE went 9 to 15 months before a correct diagnosis
was made. Acute rheumatic fever and rheumatoid arthritis were
the usual misdiagnoses for children, teenagers, and young
adults. Few physicians diagnosed the illness as readily as now.
Today SLE is correctly diagnosed much more quickly; indeed,
most physicians have more trouble diagnosing acute rheumatic
fever than SLE. Whereas the physicians practicing in the 1950s
and early 1960s had seen many cases of acute rheumatic fever,
few had ever cared for patients with a diagnosis of SLE. The
presence of renal disease made it easier to diagnose SLE;
nevertheless, many patients with renal disease were thought to
have other problems, the most frequent being poststreptococcal
glomerulonephritis, idiopathic glomerulonephritis, or idiopathic
nephrotic syndrome.
In the pre-steroid era, patients with SLE often died of acute
toxic lupus. These patients did not live long enough to develop
renal failure [48]. With the introduction of corticosteroids in
1949, many patients with SLE received "low" doses of
prenisone (10—30 mg/day), a dose sufficient to ameliorate most
symptoms [41—46]. These patients often developed renal failure,
however [50, 57]. During the 1960s and 1970s there was a
progressive increase in the understanding of fluid and electro-
lyte balance and the need to treat hypertension [58], as well as
better antihypertensive medicines, improved antibiotics and
diuretics, their more effective use, and the widespread avail-
ability of dialysis. In every decade since 1930, the prognosis of
patients with SLE has improved [59]. The improvement in the
practice of internal medicine permitted patients with SLE to
live longer, but their longevity allowed the development of renal
failure in some. With the introduction of vigorous toxic therapy
for SLE renal disease, more patients died of infections than
from renal failure.
The median survival of patients with SLE and renal disease
was less than one year during the 1940s and first half of the
1950s [49, 50, 57, 60, 61]. With the introduction of high doses of
corticosteroids, early detection, and better medical manage-
ment, the median survival rose to approximately 2.5 years in
the late 1950s [60, 61]. Between the early l960s and the early
1970s, median survival rose to approximately 5 years [62—64].
Our own experience at the NIH indicates that since 1970,
patients with SLE nephritis who were treated with cyclophos-
phamide early in the course of the disease have a median
survival of greater than 15 years, and their progression to
end-stage renal disease is minimal (Fig. 1). Those treated with
corticosteroids and azathioprine have a median renal survival of
10 years (Fig. 1). Thus, like extrarenal SLE and SLE as a
whole, the prognosis for renal SLE and even severe renal SLE
has progressively improved. The reasons for this improvement
in prognosis are multiple, but vigorous control of hypertension
and reduced reliance on long-term, high-dose corticosteroids
probably are the two most important.
The renal biopsy
Is renal biopsy useful? Yes. Is it absolutely necessary? I
doubt it. These 12 words could incite stormy debate among
hundreds of experts for months and culminate in some general
agreements but no satisfactory resolution. Why is renal biopsy
in SLE such a charged issue? I believe that the answer lies in
the history of the histologic evaluation of renal biopsies in
patients with SLE.
After the initial descriptions of renal involvement in patients
with SLE, the prevalence of such abnormalities was analyzed.
The data depended on the source of the material: autopsy,
biopsy of selected patients, biopsy of unselected patients,
biopsy plus clinical findings, etc. Some of the early estimates of
renal pathology in SLE patients were 62% of 90 unselected
living patients [50] and 71% of an autopsy series [65]. Two
groups dominated the classification of biopsies, Pollack and
colleagues [60] and Baldwin and colleagues [61]. Biopsies were
divided into histologic groups with associated clinical charac-
teristics, especially with regard to the prognosis for renal
failure. This approach represented a departure from the view of
Harvey and coworkers, who maintained that often it was
impossible to correlate the clinical evidence of renal involve-
ment with the histologic findings at autopsy [66].
One of the histologic patterns was called focal proliferative
lupus nephritis [611 or glomerulitis [60]. This biopsy picture was
characterized by proliferation of some portions of some
glomeruli without substantial tubular or interstitial inflamma-
tion. A more severe disease was associated with a histologic
pattern termed diffuse proliferative lupus nephritis [61] or lupus
glomerulonephritis [60]. This was a picture of more extensive
proliferation, often with necrosis, and with tubulointerstitial
inflammation. Whereas patients with the first histologic type
were thought to respond to low doses of corticosteroids and
usually did not progress to renal failure, the group of patients
with the diffuse proliferative biopsy picture required large doses
of corticosteroids and even then frequently died of renal failure.
Some patients progressed from the milder to the more severe
histologic picture. A third histologic type was membranous
772 Nephrology Forum
a)
'V
'V
C
a)
0C
0
0
'V
-D00
0.8
0.2
0.0
16020 40 60 80 100 120 140
1.0
5)
'V
a)
2 0.6
0
C
0
> 0.4
.0
'V
.00
0-
brane. These last two groups generally had an excellent prog-
nosis, but an occasional patient subsequently developed one of
the other lesions.
This histologic classification scheme represented an admira-
ble attempt to determine clinicopathologic correlations that
would help in the management of patients. The predictions were
more or less accurate. In an attempt to emphasize the differ-
ences among histologic types, however, researchers underem-
phasized the difficult eases—those that could not easily be
pigeonholed and those that changed from one type to another
[64, 67—71]. These histologic classifications nevertheless were
used to dictate therapy for lupus patients for more than 20
years. Ultimately, additional modifications of the classifications
have emerged, and these have been combined with electron
microscopic analyses [72—78]. These studies suggest that rather
than regarding the biopsy classification for any individual
patient as indicative of a fixed and final diagnosis, it should be
regarded as representing but one point in a dynamic process,
especially because in half of the patients the histologic classifi-
cation changes if biopsy is repeated [70],
Regardless of the specific histologic classification, the follow-
ing abnormalities are believed to be indicative of active glomer-
ular inflammation associated with a bad prognosis: segmental or
diffuse hypercellularity, segmental necrosis, karyorrhexis,
fibrinoid deposits along the basement membranes (especially
new deposits that may be tinctorially different from the rest of
the membrane), wire loops, hematoxylin bodies, hyaline
thrombi in the capillaries, epithelial crescents, and subendo-
thelial deposits (demonstrated by fluorescence microscopy and
confirmed by electron microscopy). Interstitial infiltration with
lymphocytes and plasma cells also is indicative of active
disease.
In the past 10 years, researchers increasingly have empha-
sized renal scarring as a prognostic factor [68, 73, 79—821.
Evidence of scarring includes hyalinized glomeruli with sclero-
sis, fibrous crescents, periglomerular fibrosis, and interstitial
fibrosis. Extensive scarring in the presence of substantial active
renal inflammation carries a grave prognosis with regard to the
development of total renal failure and justifies vigorous treat-
ment, On the other hand, in the absence of active inflammation,
vigorous treatment may confer little benefit. Thus, the degree of
specific, individual abnormalities in a given renal biopsy can be
as important in determining prognosis and therapy as is the
histologic group into which the biopsy findings may be placed.
Just as the renal biopsy changes over time, the urinalysis,
"the poor man's kidney biopsy," changes over time. More-
over, just as the biopsy is not a perfect prognosticator, the
urinalysis is not a perfect indicator of the histologic picture.
Nevertheless, generalizations can be made from the urinalysis,
just as generalizations can be drawn from the biopsy. Patients
with massive proteinuria and the nephrotic syndrome without
microscopic hematuria usually have membranous disease
[83—861. Substantial proteinuria with microscopic hematuria
and cellular casts suggests diffuse proliferative or membrano-
proliferative disease. Red cells and white cells in the urine (in
the absence of infection) in association with lesser degrees of
proteinuria suggest focal-segmental or diffuse glomerular in-
flammation. Notwithstanding, occasional patients can have
many red cells in the urine without important histologic abnor-
malities. The microscopic hematuria sometimes is associated
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Fig. 1. Patients with SLE and diffuse glomerular disease with evidence
of active renal inflammation (hematuria, proteinuria, casts) were
randomized to receive intravenous cyclophosphavnide (0.5—1.0 mg/kg!
month for 3 months, then every 3 months for another 4—5 years), oral
cyclophosphamide (50—100 mg/day), oral azathioprine (50—150 ,ug/day),
or both oral cyclophosphamide and oral azathioprine, each added to
low doses of prednisone (0.5 mg/kg/day tapered to 0.25 mg/kg every
other day), or prednisone only (1 mg/kg/day for 2—3 months with
subsequent taper per the !udgment of the physician). Renal function
was evaluated regularly. The figures plot the probabihty of retaining
renal function over time (avoiding renal failure) in patients receiving
prednisone only (PRED), prednisone plus azathioprine (AZA), intrave-
nous cyclophosphamide plus prednisone (TV-CY), oral eyclophos-
phamide plus prednisone (P0 CY), or oral prednisone plus oral
eyelophosphamide plus oral azathioprine (CY + AZ). In the upper half
of the figure, all of the patients receiving cyclophosphamide in any
regimen are combined and compared with those receiving prednisone
only. The number of patients in each group is indicated. In the lower
figure, three separute groups are compared, with the number of patients
shown in parentheses. The data shown are for patients at high risk for
the development of renal failure: those with some important degree of
scarring on renal biopsy.
disease, often described as identical to that of idiopathic
membranous disease, but which in fact usually has more
mesangial proliferation. Approximately 20% of patients with
membranous disease developed renal failure within a 5-year
followup period.
Approximately one-third of unselected patients with SLE had
one of two additional biopsy types: a normal biopsy or minimal
glomerular involvement. This last, or fifth, group had focal
areas of mesangial or endothelial hypercellularity and mild
segmental and focal thickening of the capillary basement mem-
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with the ingestion of nonsteroidal antiinflammatory drugs,
especially aspirin. Contrariwise, occasional patients with a
normal urinalysis can have a very abnormal biopsy [88]. Al-
though almost all patients with SLE have some degree of renal
pathology demonstrable histologically [87—89], most patients
with normal urinalyses have an excellent prognosis for retaining
adequate renal function. Thus, the urinalysis often provides a
general idea about the severity of the renal pathologic process.
If there is information regarding the previous course of the
patient, the urinalysis may be even more valuable as an
indicator of renal pathology and prognosis.
An additional consideration is the point in the course of
disease when the biopsy is performed. Patients with active
nephritis and microscopic hematuria who are biopsied early in
the course of their disease can have mesangial [76, 771, focal-
segmental [90, 91], diffuse proliferative [61, 911, or membrano-
proliferative [61, 92] disease. Patients with rapidly progressive
renal insufficiency commonly demonstrate marked endothelial
cell proliferation and many crescents [93]. Slowly progressive
renal failure associated with a relatively unremarkable urinaly-
sis frequently characterizes patients with interstitial nephritis
[94, 95] or glomerulosclerosis [68, 69, 72, 73, 96, 971. Patients
with active disease early in their course can develop slowly
progressive renal failure, and the biopsy pattern can shift from
active disease and inflammation with little scarring to a predom-
inance of scarring with varying degrees of active disease. Thus,
whereas an early biopsy might not predict the ultimate course
or the later biopsy type, a late biopsy can demonstrate disease
that is incompletely reversible.
I have focused in this presentation on glomerulonephritis
because it is the most common form of significant renal disease
in patients with SLE and is the subject of the greatest contro-
versy. Obviously we must consider other causes of renal
disease. Patients with SLE are especially predisposed to infec-
tion [98], and corticosteroids heighten this predisposition [98,
99]. There is a logarithmic increase in the number of infections
as corticosteroid doses are increased [99, 100]. Urinary tract
infections are the most common, accounting for about 50% of
all infections in patients with SLE. As a result, one should
carefully search for such infections before attributing hematuria
plus pyuria to glomerulonephritis. In addition, patients with
SLE can have renal vein thrombosis [100, 101], amyloidosis
[102, 1031, or cystitis [104]. Antibodies may be deposited in the
renal interstitium [105, 1061, and tubulointerstitial inflammatory
disease predominates in some patients with little glomerular
involvement [94, 95]. Finally, drugs given for extrarenal SLE,
especially nonsteroidal antiinflammatory drugs, can produce
impairment in glomerular filtration rate [107, 1081. It would be a
mistake to vigorously treat for rapidly progressive glomerulo-
nephritis when withdrawal of such drugs could ameliorate the
problem.
In summary, urinalysis allows some prediction of the biopsy
picture, but it is far from a perfect predictor. The biopsy assists
in the prognosis for renal failure, although its prognostic ability
early in the course of illness is not as powerful as it is later. An
early biopsy can lack sufficient prognostic power to allow the
physician to accurately balance the potential risks and benefits
of alternative therapies. On the other hand, if the biopsy is
carried out too late, the bad prognostic information might arrive
too late to allow the patient the full benefit of treatment. In fact,
despite the voluminous literature extolling the prognostic vir-
tues of renal biopsy in patients with SLE, contrary views are
held [109, 1101. It is thus obvious that information obtained
from the renal biopsy should be used in conjunction with the
entire clinical picture in the management of patients with SLE.
Lessons from mice
The renal histology of patients with SLE is better understood
when one looks at various murine models of lupus-like ill-
nesses. One strain develops diffuse proliferative disease. Early
renal histology shows only mesangial proliferation, however.
When the mesangium is overwhelmed with various immune
complexes, capillary loop disease becomes apparent. Thus, the
kidneys of a 5-month-old (NZB x NZW)F1 female can show
mesangial disease, whereas 2 months later there is more severe
and diffuse disease. Another strain develops membranous dis-
ease with mild proliferative changes but marked interstitial
inflammation; however, initially there is only mesangial prolif-
eration and minimal basement membrane thickening.
A third strain has renal disease ultimately characterized by
arteritis and membranoproliferative disease, but early renal
histologic study discloses only mesangial disease. At this stage
several mice are treated with cyclophosphamide. Whereas most
of the untreated littermates had severe renal disease with
azotemia or have died, the mice treated with cyclophosphamide
had only mild mesangial proliferation. Other littermates were
treated after the onset of membranoproliferative disease, but
the treatment was stopped one month ago. Renal histology
revealed a reversion to only a mesangial lesion with slight
basement membrane thickening. If treatment continues to be
withheld, more severe disease will recur and the mouse will die
of renal failure. If the treatment is continued for several more
months, the mice will live essentially a normal life span (see
section on cyclophosphamide).
Although many differences exist between mice and humans,
the lessons from the mice are being confirmed in patients.
Mesangial disease can be either benign or a prelude to more
severe disease. Biopsies can get "worse"; biopsies can get
"better" with treatment. Treatment must be continued for a
long enough period to bring about a "remission."
Serology
A great deal has been written on the subject of serologic
testing for diagnostic and prognostic purposes [111—117]. With
regard to the latter, correlations have been made between high
titers of anti-DNA antibodies and renal disease in SLE. Precip-
itating anti-DNA antibodies also have correlated with renal
disease. We have found that qualitative properties of anti-DNA
antibodies such as affinity, ability to form precipitates, and
ability to fix complement do correlate with the severity of renal
disease independent of the total amount of anti-DNA [1181.
Others have suggested that high p1 (isoelectric point) anti-DNA
may be especially nephrotoxic.
In such studies, it is important that the study population be
carefully specified. If the population comprises all SLE pa-
tients, a correlation exists between the amount of anti-DNA and
the presence of renal disease. If the study population is re-
stricted to patients with renal disease, however, no correlation
can be ascertained between increasing amounts of anti-DNA
and increasing renal disease. Moreover, in my experience, the
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patients with the very highest amounts of serum anti-DNA
antibodies (in the 200 pgIml to 4 mg/mI range) were most readily
treated successfully, especially in terms of preventing end-stage
renal disease. It was the patients with lower to intermediate
amounts of anti-DNA (8 g/ml to 50 tg/ml) that were often the
most resistant to therapy.
I do not believe that we should treat the anti-DNA level in
and of itself; if the anti-DNA proves to be of the deleterious
type, however, I might modify my position. I worry more about
low complement than about high anti-DNA. Low C3 occurs in
patients with SLE secondary to decreased production (chronic
disease) and increased consumption (classical and alternative
pathways). Low C4 is a more sensitive indicator of the classical
pathway, as the absolute amount of normal serum C4 is much
less than the absolute amount of serum C3. Total hemolytic
complement activity is often the most useful complement
measure. In patients who have previously demonstrated a flare
in renal disease with falling complement in the presence of a
rising anti-DNA, one might bc justified in treating the serologic
alterations. This approach has been advocated for years [1111.
A randomized trial evaluating vigorous therapy of serologic
abnormalities would be welcome.
It is not clear that circulating immune complexes are the only
pathogenetic materials in lupus glomerulonephritis. Because
DNA has an affinity for glomerular basement membranes [119],
it is possible that the antigen binds to the glomerulus and that
circulating antibody then attaches to the bound antigen, thereby
initiating the inflammatory process. Thus factors that reduce
any of the following should reduce renal inflammation: antigen-
antibody complexes that reach the kidney; antigens that bind to
the kidney, especially those to which there are circulating
antibodies; and antibodies that bind to the kidney. Comple-
ment-fixing antibodies appear to be especially deleterious;
therefore, eliminating them is particularly desirable [116, 1171.
In terms of serologic testing, the antibodies in the serum may
reflect those that induce renal pathology [1181, or the serum
may be depleted of such antibodies when the antibodies are
preferentially found in the kidneys [1151. Thus, serologic testing
is of some prognostic value, but it correlates less well with the
ultimate development of end-stage renal disease than originally
thought.
SLE and end-stage renal disease
Patients with SLE who develop end-stage renal disease over
an extended period despite substantial corticosteroid therapy
with or without immunosuppressive drugs can be managed with
chronic dialysis. Although several groups have reported im-
provement of signs and symptoms of extrarenal SLE during
chronic hemodialysis [120—123], this is not a uniform effect.
Dialysis patients with SLE have no difference in mortality rate
[1241, and they can undergo renal transplantation successfully
[125—127], although recurrence of SLE in the graft has been
reported in some patients [126, 1271. In patients with relatively
recent onset of renal disease, function can deteriorate to a point
of requiring dialysis; some such patients can, with treatment,
recover sufficient renal function to no longer require dialysis
[120, 1211.
Treatment of StE nephritis
How can we determine whether specific treatment for pa-
tients with SLE and nephritis is useful? We can rely on an a
priori view, experience, a series of patients, or randomized
trials. Since the cause or causes of SLE are unknown, an a
priori view would be tenuous.
Personal experience is of marginal utility in a disease such as
SLE, which is characterized by marked variability in clinical
course. A favorable experience with plasmapheresis or boluses
of methylprednisolone in a few patients can evoke an unduly
enthusiastic opinion of that treatment; an unfavorable experi-
ence could produce an unwarranted pessimistic view. The truth
might be between the two assessments. Experience with one
treatment in a large number of patients might provide a better-
grounded view. One must remember, however, that experience
with even large series of SLE patients can be judged only
against an expected outcome.
If patients uniformly benefit from a therapy without having
identifiable side effects (or with acceptable side effects in terms
of severity and incidence), the therapy rapidly becomes accept-
able. Examples are digitalis in congestive heart failure and
penicillin in streptococcal disease. For SLE, this approach is
not as clear-cut. As I noted caner, SLE has been characterized
by a steady improvement in prognosis over the past 40 years
because of a variety of reasons. An uncontrolled study would
necessarily use historic controls—either consciously or subcon-
sciously—and therefore provide misleading conclusions. Any
treatment in an uncontrolled series will appear to be beneficial
as long as it is not inherently detrimental. We therefore must
question carefully the value of papers reporting results of a
series of patients treated with a particular agent in an uncon-
trolled fashion. What is particularly distressing is that such
papers often call for a randomized trial, but the very same
authors proceed to report the results of a second uncontrolled
series without performing the randomized trial. Unless a ther-
apy is remarkably effective and nontoxic, such an approach is
inappropriate whether or not the treatment ultimately is deter-
mined to be beneficial in a randomized trial.
Randomized trials overcome the problem of changes in
natural history over time. They also eliminate the variable of
changes in prognosis over time due to improved general medical
care. Nevertheless, randomized trials are not inherently per-
fect. Patients in a randomized trial might not be assigned
appropriately to different treatment groups by chance. The
fewer stratification subgroups prior to randomization, the more
likely it is that one will arrive at an unbalanced result. On the
other hand, the greater the number of stratification subgroups,
the fewer patients per subgroup; this problem obviously casts
doubt on the findings for numerical reasons. Physicians from all
over the country, in fact all over the world, call or write me
seeking information about the latest results of our randomized
trials or asking advice. The failure of these and other physicians
to enter their patients into ongoing or new randomized trials
slows the acquisition of new information. It is estimated that
there are 10,000 to 50,000 new cases of SLE per year in the
United States. If 50% of these patients have renal disease and
20% of those have serious renal disease, between 1000 and 5000
patients per year could be entered into randomized trials in the
US. Instead, fewer than 30 patients are entered into randomized
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trials annually. Approximately 99% of patients, therefore, are
treated on the basis of physicians' idiosyncratic, personal
preferences or dogmatic viewpoints. I regard this as a great
irony; I believe that I know how to treat patients with SLE and
nephritis as well as anyone, and yet I do not know the best
treatment. Randomized trials have taught us much, but contin-
ued randomized trials will provide additional important infor-
mation. Those data will not be forthcoming as quickly as
possible if the accrual rate into randomized trials is less than 1%
of eligible patients.
Drug therapy
Corticosteroids. Oral corticosteroids have been the mainstay
of the treatment of lupus nephritis. Nevertheless, the basis for
this treatment is tenuous. Its rationale is in part historic.
Corticosteroids received widespread acclaim after their intro-
duction into clinical medicine. It rapidly became apparent that
symptomatic SLE was readily controlled in most patients by
corticosteroids and that the acute toxic lupus syndrome, previ-
ously fatal, could be effectively treated with moderate doses of
corticosteroids. The effectiveness of corticosteroids in extrare-
nal SLE was then extrapolated to lupus nephritis. These results
were obtained simultaneously with the initial use of nitrogen
mustard in the therapy of lupus nephritis. Had nitrogen mustard
achieved widespread use prior to the introduction of cortico-
steroids, the history might have been different.
The use of steroids was bolstered when Pollack and col-
leagues promoted high-dose corticosteroids in the treatment of
lupus nephritis [57]. For two decades this report was incorpo-
rated into all textbooks on the subject. The paper therefore
deserves scrutiny. First, it is not a randomized trial. Patients
treated with low doses of corticosteroids from 1953 to 1955
were compared with those treated with high doses of cortico-
steroids from 1955 to 1957. As I already have noted, the
prognosis of patients with SLE has been improving steadily
since the 1940s. Thus it is possible that patients in the later
group fared better than did those in the earlier for reasons other
than differences in corticosteroid dosage. What variables could
account for decreased morbidity and mortality in SLE patients?
As I noted earlier, some factors that readily come to mind are
earlier diagnosis, earlier therapy, better use of antibiotics,
improved knowledge of fluid and electrolyte balance, and better
supportive care. Second, the data in the paper support the idea
that the two groups of patients were not comparable. The
patients treated from 1953 to 1955, who received low doses of
corticosteroids, had worse renal function at entry [57]. An
average serum creatinine of 2.0 mg/dl in an era with inadequate
antihypertensive treatment and no dialysis was associated with
an extremely poor prognosis. In fact, the paper has a most
informative datum that has been ignored by almost all students
of lupus nephritis: patients with a BUN greater than 30 mg/dl
treated with low doses of corticosteroids lived 2.5 times longer
than did those treated with high doses of corticosteroids [57].
Thus the widely held view based on this study that high doses
of corticosteroids are better than low doses of corticosteroids
for severe lupus nephritis is without adequate factual support.
Moreover, another study that directly compared low and high
doses of corticosteroids failed to note a difference in outcome
[128]. However, it has become almost sacrilegious to suggest
that high doses of corticosteroids are no better than are low
doses in the treatment of lupus nephritis. Is it possible that the
toxic effects, especially predisposition to infection and poorly
controlled hypertension, outweigh or counterbalance the bene-
fits of higher doses of corticosteroids? My belief is that our
increased awareness of the problems as well as better and faster
treatments of them would allow the potential benefits of higher
doses of corticosteroids to be demonstrated in a well-designed
trial, a trial likely never to be done.
In an attempt to avoid the side effects of high-dose daily
steroids, Ackerman used alternate-day steroids to treat lupus in
general and lupus renal disease in particular [129]. Unfortu-
nately, the experience with this treatment in young patients
with active nephritis is inadequate to provide information and
thus a valid opinion regarding its efficacy. But, in recent years
the use of boluses of intravenous methyiprednisolone has been
borrowed from the experience with renal allograft rejection
[130]. Either 1 g or 1 g/M2 is given daily for 3 days. This
treatment has been adopted by many physicians with the view
that it probably is of some benefit and that it probably will not
be harmful. Although many patients respond initially, the
long-term followup of such patients has been inadequate; thus
the efficacy of boluses of intravenous methylprednisolone has
not been demonstrated. In addition, although generally safe,
complications have been noted, including seizures [1311, seri-
ous infection [132], anaphylaxis [133], arrhythmias [134], and
sudden death [1351. This therapy therefore should be regarded
as experimental, and its value should be demonstrated in a
randomized trial.
Azathioprine. I believe that the benefits and side effects of
azathioprine (AZA) in patients with SLE are inadequately
understood. Azathioprine given in full doses with allopurinol
can cause fatal bone marrow suppression, a drug interaction
inadequately recognized even in published reports. The drug
appears to predispose to cancer of the skin and uterine cervix
[136] and to central nervous system (CNS) lymphomas. Idio-
syncratic reactions can include acute granulocytopenia in the
first 10 days of treatment and an allergic reaction characterized
by fever, rash, and hepatitis. Azathioprine might not be of
benefit, and could be detrimental, in certain CNS manifesta-
tions of SLE.
On the positive side, azathioprine might be of greater benefit
than is widely believed in patients with SLE. My own unpub-
lished experience is that it is quite useful in some patients
suffering from resistant discoid lupus. With regard to renal
disease, a number of studies offer conflicting results. The early
studies were positive, demonstrating benefits in terms of de-
creased steroid requirements, fewer hospitalizations, and im-
proved survival rates [137]. One widely quoted, early study
omitted data relating to early in-hospital death in patients
assigned to AZA, thereby providing information that might
have been biased in favor of the benefits of AZA [137]. Several
subsequent trials have demonstrated little benefit from AZA
[138, 139].
I believe that our studies at the NIH provide some insight:
only a subgroup of patients benefits from AZA therapy [140].
These were patients with disease that was neither of the mildest
degree (which responded to corticosteroids alone) nor the most
severe (which did not respond to either corticosteroids or
corticosteroids plus AZA). This intermediate group appeared to
benefit from AZA plus steroids in the treatment of their lupus
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NZB F Black 9/9 11/11
NZB M Black 7/7 13/13
(NZB x NZW)F1 F Agouti 9/9d 1/10
(NZB x NZW)F1 M Agouti 8/8 12/12
MRL-lpr/lpr F White 0/11 0/9
MRL-lpr/lpr M Whitc 1/12 0/8
BXSB F Brown 14/14 6/6
BXSB M Brown 2/9 0/9°
All females 32/43 (74%) 18/36 (50%)
All males 18/36 (50%) 25/42 (60%)
Totals 50/79 (63%) 43/78 (55%)
nephritis [140]. The classification we used might not be the only
one or the best one, but it does point out that subgroups of
patients might respond to a therapy that does not benefit others.
A second insight into the potential effectiveness of AZA in
patients with lupus nephritis has come from long-term followup
of patients. We found that even a 5—year followup is too short
to determine the relative effectiveness of the various commonly
used treatments for lupus nephritis. Figure 1 illustrates this
point. Whereas there was no difference in progression to
end-stage renal disease (ESRD) among the 3 drugs during the
first 5 years, a substantial difference was apparent after 10
years, Almost all patients randomized to receive corticosteroids
alone developed ESRD within 10 years, whereas only about
one-half of the patients receiving AZA plus corticosteroids
progressed to ESRD. It thus is necessary to continue prolonged
followup observations (without the introduction of additional
therapies to confound the results) to determine the real benefits,
and toxicities, of various treatments. With regard to AZA, we
can conclude that it is of some benefit in delaying the develop-
ment of ESRD in some patients when compared with cortico-
steroids alone, bul that it might not be as effective as cyelo-
phosphamide (Fig. 1).
Cyc/ophosphwnide. Cyclophosphamide is metabolized, pri-
marily in the liver, to active metabolites that alkylate and
phosphorylate macromolecules [141]. A toxic drug, cyclophos-
phamide can cause hemorrhagic eystitis, bladder fibrosis, blad-
der carcinoma, sterility, and possibly leukemia or other malig-
nancies [142—146]. In experimental animals, cyclophosphamide
is especially effective at reducing antibody production to exper-
imental challenge—with a high therapeutic index. It also is very
effective in the treatment of murine lupus, provided it is started
at the proper time and is given in the proper dosage [147—150].
in fact, a randomized study of different strains of murine
50 mg/kg/week 3.5 months
a Cyclophosphamide led to a significant and substantial prolongation
in survival, reduction in renal immuno- and histopathology, and no
major complications.
Not done as part of this study. Other studies have demonstrated
benefit in this group as welt. For NZB males, the dosage and time of
onset was similar to that for NZB females; for BXSB females., the time
of onset and dosage was similar to that of (NZB x NZW)F1 mates.
lupus has been quite informative [147, 149]. Although one
cannot extrapolate the results precisely and directly, I believe
that an appreciation of this murine study goes a long way
toward our developing the ability to evaluate the human trials,
This study included several strains of mice that develop an
SLE-like illness. The pace of illness varies between the sexes in
several of the strains and from one strain to another (Table I,
saline controls). The optimal age for initiating treatment and the
optimal dosage schedule also vary from group to group (Table
2). As a result of these variables, a randomized study has
produced a paradox. Cyclophosphamide treatment in the
proper dosage schedule, when started at the optimal age for
strain and gender, proved to be a highly effective treatment for
each strain and for both sexes (Table 2). But when these groups
with different natural histories and dosage schedule require-
ments were combined into a single study with one fixed
treatment regimen, no significant benefit of cyclophosphamide
was demonstrated (Table 1). This result illustrates the great
difficulty in documenting that a therapy is effective in a heter-
ogeneous group. Despite this difficulty, in human studies
cyclophosphamide has proved effective in the short-term treat-
ment of lupus nephritis and in delaying or preventing ESRD
[15 1—155]. It should be noted, however, that definitive benefit
was not demonstrable until 10 years of followup (Fig. 1). At 5
years, cyclophosphamide was no better than was prednisone
alone or prednisone plus AZA. These results emphasize the
critical requirement for long-term monitoring and for avoiding
the introduction of new therapies into the various treatment
groups in order to judge the merit of each therapeutic strategy.
Even among our own group, I personally have had to fight an
uphill battle to keep our studies going for a long period of
followup without succumbing to the desires of my colleagues
who wished to re-randomize patients into newer studies and
terminate prematurely the studies into which pafients were no
longer being randomized, but in which patients were still being
monitored.
My experience with murine lupus has taught me the need for
survival studies to give substantive meaning to therapeutic
interventions. This experience has carried over into my think-
Table 1. Results of a randomized trial of cyctophosphamide in the
treatment of murine tupusa
Strain or
cross Sex Color
Number surviving/Total5
CYC Saline
Table 2. Cyclophosphamide therapy initiated at the proper age is
effective in mice of both sexes with mnrine lupus
Strain or
cross
Effect
Sex of CY Dosage
Age
initiated
NZB F Beneficiala 90 mg/kg/month 11 months
NZB M Not done5
(NZB x NZW)F1 F Beneficial
Beneficial
4.5 mg/kg/day
9t) mg/kg/month
5 months
4.5—6.5 months
(NZB x NZW)F1 M Beneficial 25 mg/kg/week 11 months
MRL-lpr/lpr F Beneficial 100 mg/kg/week 2—4 months
MRL-lpr/lpr M Beneficial 100 mg/kg/week 2—4 months
BXSB F Not done5
BXSB M Beneficial
a Mice were randomized without regard for color or sex into two
groups; one received cyclophosphamide (CY), the other received
saline. The age at which treatment was initiated (5 months), the
duration of treatment (3 months), and the dosage schedule (either 90
mg/kg/month or 25 mg/kg/week) was based on previous beneficial
results with (NZB x NZW)F1 mice [148]. These data are from Ref. 147.
Survival to one year.
C The results of the 2 CY treatments (each administered to half of the
mice receiving CY) did not differ, so they were combined.
d One mouse was lost from this group.
Two mice were lost from this group.
Not significantly different from saline controls, P > 0.1.
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ing in clinical therapeutic trials. In the absence of curative or
nontoxic drugs, we must provide long-term outcome data to
justify the continued use of toxic therapies such as high doses of
corticosteroids, azathioprine, cyclophosphamide, chloram-
bucil, nitrogen mustard, prolonged apheresis, cyclosporine, and
other currently used modalities. Such long-term outcome data
are progression to renal dysfunction or death; changes in biopsy
picture, reduction in autoantibodies, and other short-term anal-
yses are insufficient.
Other lessons from the mice are applicable to patients.
Combination chemotherapy can maximize the benefits and
minimize the toxicities of individual drugs [139, 148, 149].
Occasional boluses of cyclophosphamide can allow for the
administration of a lower total dose of drug and can expose the
organism to risks such as infection, bladder problems, and
malignancy for only short periods while conferring a greater
benefit than does daily therapy [139, 148, 150, 155]. Treatment
after the kidneys are scarred is not very effective when com-
pared with treatment begun earlier [139, 147, 149, 1511. More-
over, in individuals with scarred kidneys, the infectious com-
plications of immunosuppressive drugs tend to outweigh the
advantages.
Other alkylating agents. Cyclophosphamide is one of a family
of alkylating agents [141]. Other alkylating agents have been
used to treat patients with lupus nephritis. Nitrogen mustard
has been used by a few physicians over more than 30 years;
however, its efficacy has never been demonstrated in a random-
ized trial [47J. Chlorambucil has been a favorite drug for lupus
nephritis among some physicians, but it is the subject of only
one randomized trial [153]. There is no evidence that either drug
is superior to cyclophosphamide. If it can be demonstrated that
one is equally effective and less toxic, it might gain favor. My
opinion is that chlorambucil is not less toxic; however, a
cyclophosphamide derivative without toxicity for the urinary
collecting system would be welcome. Alternatively, one could
administer cyclophosphamide with a reducing agent, thus off-
setting the bladder toxicity of the metabolites of this drug [156].
In this regard, the use of cyclophosphamide plus such an agent
to protect the bladder should be the subject of a major trial in
patients with lupus renal disease.
Experimental therapy of unproven worth
Plasmapheresis. Plasmapheresis is for some physicians a
continuation of the unscientific blood letting and leech applica-
tions of our predecessors. For others, it is an obvious treatment
for removing circulating injurious antibodies and/or immune
complexes. Its place in the management of SLE in general or
lupus nephritis in particular is still controversial [157—160].
Plasmapheresis clearly removes anti-DNA, albeit transiently. A
randomized trial of patients with mildly active SLE failed to
demonstrate benefit [157], although benefit has been suggested
for patients with more severe disease when used in association
with bolus doses of cyclophosphamide [159]. My guess is that
an acutely ill patient might benefit in the short term from
plasmapheresis, but is unlikely to benefit from it over the long
term. Studies to support or refute the use of plasmapheresis in
SLE will require careful comparisons in long-term followup
studies.
Anticoagulation. Patients with severe glomerulonephritis
have endothelial proliferation and narrowing of capillary loops
as well as circulating factors that can predispose to thrombosis.
Intracapillary thromboses and proteins involved in coagulation
have been observed in glomeruli of patients with SLE [38]. As
a result, anticoagulants, especially heparin, have been advo-
cated by some physicians [161, 162]. Pit viper venom also has
been tried [163]. A study employing a larger number of patients
is needed to determine whether interference with coagulation
has a place in the management of SLE. In particular, if a subset
of patients might benefit, definition of such a subset by a
well-designed, stratified, randomized trial will be necessary.
Patients with lupus and severe glomerulonephritis often have
hypertension and also could have cerebrovascular inflamma-
tion, so the risks of anticoagulation, such as intracranial hem-
orrhage, must be weighed against real or potential benefits.
Total nodal irradiation. This therapy is effective in mice with
lupus-like disease [164] and has been tried in a few patients
[165]. Its effectiveness must be demonstrated relative to other
therapies, such as boluses of corticosteroids or cyclophos-
phamide, before it can be embraced, even in patients apparently
refractory to oral treatment with corticosteroids and azathio-
prine.
How should we manage a patient with SLE and renal
disease?
I have many ideas on this subject, but I do not know the
answer. For our discussion, let's first consider what is known
about the problem. One must be sure that the patient's renal
disease is part of the SLE syndrome and not another problem
such as a urinary tract infection or renal cell carcinoma. The
extent and severity of renal involvement should be determined.
I will describe several patients for illustration, with the under-
standing that there are many other types of patients as well. The
first is a 34-year-old female with a 10—year history of SLE and
renal inflammatory disease for 7 years. Over the past 4 years,
the serum creatinine has risen from 1.9 to 6.8 mgldl despite
several courses of 60 mg/day of oral prednisone and, in the last
1.5 years, 100 mg/day of azathioprine. The urinalysis shows 5
red blood cells and 3 white blood cells/high-power field and
granular, waxy, and broad casts. The urine contains 0.9 g of
protein per 24 hours. Radiographs reveal small kidneys. This
patient almost certainly is past the point at which a major
therapeutic intervention would be helpful. The risks of available
therapies outweigh the potential benefits; therefore, the patient
should be prepared for the future, which will consist of chronic
dialysis with the possibility of renal transplantation.
A second patient, an 18-year-old female, has been ill with
SLE for only 3 months. Initially she had fever, rashes, pleurisy,
and pericarditis responsive to 20 mg/day of prednisone. For the
past 3 weeks, she has had increasing edema, now to the point of
anasarca. Blood pressure is 182/114 mm Hg and the serum
creatinine is 6.8 mg/dl. Although this patient has the same
creatinine level as the preceding one, the underlying pathology
is likely to be quite different. This is confirmed by the findings
of 100 red blood cells/high-power field on urinalysis and 4.7 g of
protein per 24 hours. The urine contains many granular and
some cellular casts. The kidneys are of normal size. During the
first 24 hours in the hospital, the fluid accumulation of this
patient worsens, and the urine volume decreases. There is mild
pulmonary edema and the serum creatinine rises to 8.2 mgldl.
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Such a patient can require dialysis acutely for fluid and/or blood
pressure control, even if not for azotemia. Unlike the last
woman, this patient should be viewed as having potentially
reversible disease. We do not know how best to treat this
patient, but therapies such as bolus corticosteroids (1 g/M2
methylprednisolone daily for 3 days) under cover of dialysis
with vigorous control of the hypertension are logical initial
treatments. Corticosteroids should be continued at approxi-
mately 0.5 mg/kg/day oral prednisone. It is unclear whether
plasmapheresis would be of additional benefit. As soon as the
hypertension and fluid problems are under better control, short-
and long-term treatment plans can be instituted. What should
these be? Data support the use of cyclophosphamide for long-
term preservation of renal function. If the patient could not be
entered into a randomized trial, a reasonable treatment plan
would be 0.75 to 1.0 g/M2 cyclophosphamide intravenously
monthly for 6 to 8 months, followed by an injection every 3
months for an additional 1 to 3 years. The prednisone would be
tapered slowly to a maintenance dose of around 15 to 20 mg
every other day. Would monthly boluses of corticosteroids
work just as well as cyclophosphamide and produce less
toxicity? Would the addition of monthly boluses of corticoste-
roids to monthly boluses of cyclophosphamide add more ther-
apeutic benefit than harm? We need randomized trials to
answer these questions as well as to determine the duration of
treatment with boluses of corticosteroids, boluses of cyclophos-
phamide, or both.
I should point out that a renal biopsy was not obtained for
either of these 2 patients. A biopsy is useful when the results
help to direct treatment. In neither case would a biopsy have
altered the therapy.
The second patient has a remarkable course. After a stormy
2 weeks, the clinical picture brightens. Two months later, on 15
mg/day of prednisone and boluses of cyclophosphamide every 3
to 4 weeks, she has a serum creatinine of 2.4 mg/dl, 1 to 5 red
blood cells/high-power field, 0.6 g of protein in the urine per 24
hours, and a blood pressure of 114/76 mm Hg. One year later
the serum creatinine is 1.3 mg/dl and the urine is essentially
normal. She has received 9 injections of cyclophosphamide,
and the prednisone dose is 15 mg every other day. Should the
cyclophosphamide be stopped? She would like to have children
in the future; yet if she had to choose, she would choose
infertility over dialysis. We need a study to determine the
relative risks versus benefits of long-term cyclophosphamide
therapy. Should the steroids be tapered to zero? My personal
experience is that such a patient will be less likely to have an
exacerbation of renal disease if the steroids are continued at the
current dosage, 15 mg prednisone every other day, which is
virtually devoid of side effects. I have no hard data to support
that contention, only uncontrolled observations. Do we need
such a study? This issue is less compelling because the therapy
is not toxic. I would like to have my view proved (or disproved)
by a randomized trial, but such a trial would have a low priority.
Cyclophosphamide administration was continued for 2 years,
after which it was stopped, and the renal disease remained in
remission for several years. The patient graduated fron college
and medical school. She is now 27 years old and wishes to have
children. The serum crcatinine is 1.4 mg/dl and the urinalysis
normal. What should we advise? Would the advice be different
if she had had an exacerbation of renal disease 4 years ago and
had been treated with 28 monthly boluses of methylpredniso-
lone and if her creatinine were now 1.4 mg/dl? What if she had
had the exacerbation and her creatinine was now 2.5 mg/dl?
What if she had had the exacerbation and the serum creatinine
were now 1.4 mg/dl but the urine showed 10 red blood
cells/high-power field and 1.2 g of protein per 24 hours? I pose
these questions to illustrate the need for us to think of a patient
with SLE and renal disease in terms of an entire lifetime rather
than in terms only of the next few weeks or months.
A third patient has had SLE for one year starting with a
multisystem illness at age 17. She responded to 20 mg/day of
prednisone. For the past 3 months, she has noted edema and
fatigue. The serum creatinine is 0.9 mg/dl. The urine contains
4.5 g/day of protein and 75 red blood cells/high-power field.
There are many granular casts; mixed cellular and red blood cell
casts are present. Does she need a biopsy? We biopsy such
patients if they are participants in randomized trials. My
nephrology colleagues at the NIH would argue that a biopsy
would help us to better predict her outcome, and therefore to
treat, even if the patient were unwilling to enter a study or were
not eligible for some reason. I believe that this patient's
prognosis involves a substantial risk of progression to end-stage
renal disease by age 30 without vigorous and specific treatment
for the renal disease, and that a biopsy is not needed to dictate
therapy. I also believe that standard therapy with corticoste-
roids alone would not provide as great a likelihood of our
forestalling the renal failure as would treatment with cyclophos-
phamide (see Fig. 1).
What if the urine showed 4.5 g/day of protein but only 10 red
blood cells/high-power field and granular casts? I would not be
certain of the outcome and would welcome additional informa-
tion. Such information would include renal biopsy and the
presence or absence of serologic markers indicative of a good or
bad prognosis. A biopsy showing membranous disease might
suggest less vigorous treatment than would one showing diffuse
proliferative or membranoproliferative disease. Unfortunately,
biopsy results change with time in the same individual. Should
the patient have another biopsy in 6 months, one year, two
years? Clearly, less invasive prognostic indicators are needed;
however, with currently available technology, a repeat renal
biopsy may be indicated in selected patients.
A fourth patient, another young female, presents with multi-
system disease of 3 weeks duration, 20 red blood cells and 10
white blood cells/high-power field, and 1.8 g/day of protein. The
serum creatinine is 0.7 mg/dl and the urine is sterile. Should she
have a renal biopsy now? Should she be treated with 20 to 30
mg/day of prednisone for 1 to 3 months and, if renal signs
persist, then have a biopsy? We do not know the answer to
these questions. Let's imagine that a biopsy is performed
initially and that it shows only mesangial proliferation. We treat
her with 20 mg/day of prednisone for 2 months. The urine now
shows 10 red blood cells and S white blood cells/high-power
field and 1.1 g of protein per day. The serum creatinine is 0.6
mg/dl. She will be followed by a rheumatologist in a rural area.
What should we advise? Again, we don't know the answer.
(Would our advice be different if the urine protein was 3.5
g/day? In this case a biopsy is indicated.)
The normal renal function allows room for error and usually
leads such patients to be "undertreated" early in their disease.
Yet, in this particular patient, the mesangial disease may
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Table 3. Effect of dosage and time of initiation of therapy in female
(NZB x NZW)F1 mice with lupus nephritis
Median
Treatmenta
Age started
(days)
survival
(days)
None — 277
CY 1.5 mg/kg/day 150 318
AZA 1.5 mg/kg/day 150 290
MP 1.5 mg/kg/day 150 304
CY 4.5 mg/kg/day 150 394b
AZA 4.5 mg/kg/day 150 288
MP 4.5 mg/kg/day 150 309
CY + AZA + MP, each 1.5 mg/kg/day 150 409"
CY + AZA + MP, each 1.5 mg/kg/day 240 267
CY 90 mg/kg/month x 3 150 477"
CY 90 mg/kg/month X 5 150 557"
CY 90 mg/kg/month x 8 150 >600"
a 20—100 mice comprised each group. CY = cyclophosphamide; AZA
= azathioprine; MP = methyiprednisolone. Treatment was given for 3
months, which represents 1/8 of a mouse's life span (--2 years for a
laboratory mouse raised in the same environment). This is analogous to
treating a female patient for about 10 years (life expectancy of a normal
human female in the USA is about 78 years).
b Significant prolongation of survival (and reduced proteinuria and
renal immuno- and histopathology, data not shown) only in groups
receiving CY in high daily or intermittent bolus form or in combined
therapy if started early enough in the course of disease.
already have progressed in the 2-month period of followup to
diffuse proliferative disease, and slowly progressive renal scar-
ring may have begun. This hypothesis was confirmed when she
was biopsied 2 years later at another institution. The 5-year
followup showed a serum creatinine of 1.1 mgldl, 10 red blood
cells/high-power field, and 1.6 g of protein per day. This is a
"5-year cure" in oncologic terms. However, at 10 years, the
creatinine was 4.6 mg!dl and the scarring process beyond
therapy. This patient's problems raise the question: how long
can we let the nephritis progress and still be able to treat it
effectively? Again, we do not know the answer. In mice, the
earlier the treatment in the course of the lupus nephritis, the
better the outcome (Table 3) [148]. The same is probably true of
people. Does that mean that we should have treated vigorously
at first presentation after 3 weeks of illness? I don't think so.
The early biopsy may have given a falsely favorable prognosis.
Delaying the biopsy might have been preferable. The best
course might have been to watch the blood pressure, keep it
normal, and follow the patient closely. Some patients with
similar presentations never have renal signs again. Others can
progress slowly or more rapidly. We are not well enough
equipped to predict at the first visit which course will occur.
However, after a few months of persistent urine sediment
abnormalities, a biopsy should be performed so that optimal
therapy can be instituted.
Let's look at another patient, a 24-year-old female who
presents with a 3-year history of SLE and nephritis. She had
been treated by her local physician initially with 80 mg/day of
prednisone for 2 months, which had been tapered to zero over
the next 6 months. Nonrenal and renal signs and symptoms of
disease indicated an exacerbation one year later, but the blood
pressure remained at 100/60 to 120/80 mm Hg. She was re-
treated with 80 mg/day of prednisone for one month; the drug
was tapered to 20 mg/day over 4 months. At that time, 1.5 years
ago, the serum creatinine was 1.1 mgldl; urine protein, 1.4 g/24
hours; and there were 10 red blood cells/high-power field and
granular casts in the urine. Since then, the patient has been
treated with prednisone, 20 mg/day. Now her serum creatinine
is 1.6 mg/dl, she has 1.7 g of protein per day in the urine, there
are 15 red blood cells/high-power field with granular casts, and
for the past 2 months she has had blood pressures of 140/85 to
155/98 mm Hg. What should we do? The knee-jerk reaction is
different in different centers in the country. These include: (1)
biopsy and treat with high-dose steroids, (2) treat with high-
dose steroids without biopsy, (3) biopsy and treat with high-
dose steroids and azathioprine, (4) add azathioprine without
biopsy, (5) add cyclophosphamide, (6) biopsy and add cyclo-
phosphamide, (7) employ plasmapheresis and add cyclophos-
phamide with or without biopsy, and (8) give boluses of
corticosteroids with or without plasmapheresis and with or
without biopsy. Can all these different reactions be right?
Let's examine the facts. This patient has had renal disease for
3 years. The serum creatinine is now 1.6 mgldl and there is an
active sediment. The blood pressure is elevated. What is the
prognosis? If left on 20mg/day of prednisone, the prognosis for
her avoiding end-stage renal disease over the next 10 years is, in
my opinion, fair to poor. If the hypertension is vigorously
controlled, the prognosis is better. In fact, it might be as useful
to vigorously control the blood pressure, keeping it normal for
age and sex, as to treat vigorously with cytotoxic drugs. If
azathioprine is added, the prognosis is better still, especially if
there has not been too much renal scarring [140]. If cyclophos-
phamide is added to low-dose prednisone, the prognosis is still
better [139, 155]. Can we tailor the therapy to the need so as to
give the least toxic regimen and still maintain renal function?
Some would argue that a biopsy showing little or no scarring
at this point would allow less vigorous therapy (with either
corticosteroids or corticosteroids plus azathioprine), whereas
one with scarring would dictate cyclophosphamide administra-
tion. Others would argue that a biopsy showing diffuse prolif-
erative or membranoproliferative disease would call for vigor-
ous therapy. Mesangial or membranous disease would suggest
less vigorous therapy. A biopsy is performed elsewhere and
only light microscopy is available. It shows 30 glomeruli, of
which 2 are hyalinized, 5 are relatively normal, and 3 are cut so
as to make interpretation difficult. The other 20 show mesangial
proliferation with minimal capillary loop thickening. Five of
these show mild proliferative changes. There are no crescents.
Moderate interstitial inflammation is present, as is interstitial
and periglomerular fibrosis. The biopsy classifiers would call
this largely mesangial and therefore would say that the biopsy
suggests a good prognosis. Those who predict the future
according to the degree of scarring would say that this specimen
indicates a bad prognosis. How should one treat this woman? Is
azathioprine good enough? Does she require bolus treatment?
Are boluses of corticosteroids as good as boluses of cyclophos-
phamide? A study is needed to answer this question. My
interpretation of the data is that azathioprine would not provide
adequate protection against ESRD in this patient.
On the basis of the available data, the patient is given 0.9 g/M2
of cyclophosphamide intravenously. She has uncontrollable
vomiting and refuses to take the medicine again. Perhaps we
could give cyclophosphamide in a dosage schedule of 0.3 g(M2
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daily for 3 days (either orally or intravenously) instead of 0.9
WM2 in one dose so as to avoid the nausea and maintain the
benefit. Again, studies are needed to determine whether this
small change in schedule would he efficacious. My guess is that
the divided schedule would work, but that is only an educated
guess.
Comments on the patient under discussion
Let us return now to the initial patient presented. She clearly
had systemic lupus erythematosus at the time of the first
admission, She also had renal disease, probably of less than one
month's duration. Is a renal biopsy indicated? If the biopsy will
dictate therapy over a long period, it is appropriate. In other
words, if the biopsy shows diffuse proliferative glomerulone-
phritis, vigorous therapy can be instituted and subsequent renal
exacerbations can be vigorously treated, However, if the bi-
opsy is more benign, showing mild basement membrane thick-
ening or mesangial proliferation, the biopsy is of no benefit, as
another biopsy may be needed in a few weeks or months to
confirm the absence of progression. We would like to maximize
the information from the biopsy by waiting long enough for the
ultimate, full-blown disease process to present itself, but not so
long that changes become irreversible. Exactly when that is in
a given patient can be difficult to judge. The clinical findings
might help us a little, but they might not be a sufficient guide.
If a renal biopsy showed mild disease, would vigorous
therapy prevent the development of severe renal disease?
Aggressive therapy probably would protect against progressive
renal disease, but it also might predispose to toxicities that
could be avoided by less vigorous treatment. If we knew that
the probability of this patient developing severe renal disease
were very small, we would opt for less vigorous, and therefore
less toxic, therapy. On the other hand, if we knew that the
probability of severe renal dysfunction were great, we could
recommend early, vigorous treatment. Because a renal biopsy
at presentation might not provide the prognostic information,
we cannot answer the pertinent questions. I would recommend
postponing the biopsy and treating with corticosteroids in
moderate doses, controlling the blood pressure, and reevaluat-
ing every 2 to 4 weeks. That plan might be inappropriate for a
substantial minority of patients with severe histologic disease at
the first visit. It is possible that such patients would be better off
in the long run if they were treated initially with the most
vigorous therapeutic program,
If we did not biopsy, or if the biopsy showed less then severe
disease, how should we follow our patient? The answer is that
we do not know exactly how or what to follow, We do not know
how much weight to place on anti-DNA and complement levels.
A return to normal findings on urinalysis makes the physician
more comfortable, but it does not necessarily indicate that the
inflammatory process has subsided completely.
When this patient presented a year later, the renal picture
was clearer. Renal disease will definitely be a problem in her
life. Most physicians would carry out a full renal evaluation
with biopsy. The biopsy might show membranous disease with
mesangial proliferation, but almost certainly it would reveal
diffuse proliferative or mcmbranoproliferative disease. I believe
we can predict that the biopsy will be bad and that we could
treat vigorously without one. Mine is a minority opinion. The
best treatment for severe renal disease in patients with SLE is
unknown. At the NIH, we currently are randomizing patients to
receive either monthly boluses of cyclophosphamide or of
methylprednisolone with the aim of learning these drugs' rela-
tive effectiveness and toxieities. We need to know how much
drug to give, how often, and for how long. Are monthly boluses
of cyclophosphamide better than boluses of eortieosteroids?
Should we treat monthly for 6 months, one year, or some other
period? At the end of that treatment period, should we give
treatments every 3 months for an additional 1, 2, 3, 4, or 5
years? We need studies to help answer those questions. We also
need to know whether the treatments we are offering are better
than those the patient already had received. She was given a
therapy commonly employed in patients with lupus nephritis:
one course of boluses of methylprednisolone followed by high-
dose daily corticosteroids. I believe that a single course of
methylprednisolone is inadequate for many patients with severe
renal disease and SLE. Too often patients with lupus have a
flare in their disease 4 to 10 weeks after receiving the bolus.
Often the flare is as had as, or worse than, the original disease
for which the boluses were given. I believe that after a bolus is
given, there should be a commitment to monthly boluses for
several months. I do not know how many, but my "guessti-
mate" is between 5 and 10 months.
Three years later, this patient presented with a renal flare
during the third month of pregnancy. Would an abortion be
advisable? In terms of the mother's health, the answer is
unknown. We must note, however, that just as a renal biopsy is
no longer appropriate for the evaluation of every individual with
SLE, an abortion is no longer appropriate for every pregnant
patient with SLE. Two arguments in favor of allowing the
pregnancy to continue are the observations that postabortion
exacerbations of SLE can be as bad as postpartum exacerba-
tions and that some patients with lupus nephritis can be treated
successfully through pregnancy, My opinion is that the risks of
pregnancy to this mother are enormous: worsening, irreversible
renal dysfunction and uncontrollable hypertension, which could
lead to an intracerebral hemorrhage. Finally, it is unlikely that
both a healthy mother and a healthy baby would result. If an
abortion were decided against, what would be the best treat-
ment? The answer is: a vigorous one, but the details are
unknown.
As you recall, this patient had a spontaneous abortion. The
lupus was in relative remission, but the patient had a falling
complement and rising anti-DNA titer; these abnormalities
have heralded or been associated with renal exacerbations in
this patient in the past. Should she be treated on the basis of the
serologic abnormalities alone? Some physicians would urge that
she should 11111. Is another renal biopsy in order?
In general, I am not a strong believer in treatment on the basis
of serologic testing; this is one situation that argues for treat-
ment, however. We do not know whether we can prevent an
exacerbation of renal disease with less vigorous therapy than
that needed to treat the flare-up. I think that we can, but hard
data are needed to support that guess.
The exacerbation that followed the serologic abnormalities
prompted a biopsy, which showed substantial renal scarring.
The best treatment currently available for this problem is
cyclophosphamide. It remains to be determined whether total
nodal irradiation, monoelonal antibodies, or some other therapy
might be more effective or as effective and less toxic. We do not
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have enough data to be certain that vigorous treatment with
boluses of corticosteroids might not be as effective but less
toxic.
The last question deals with the patient now: a woman with
moderately impaired renal function, severe lupus renal disease
in remission for less than one year, and a history of an
exacerbation in her renal disease after a prior pregnancy. I
believe that we should discuss with the patient our concerns for
her well-being should she become pregnant again. Her course to
date suggests that she will have trouble weathering another
major renal exacerbation without losing a substantial amount of
her already compromised renal function. My usual approach to
this type of patient is to require a remission with low-dose
corticosteroid therapy ( 20 mg prednisone every other day or
5 mg/day) before a pregnancy is considered. Even then, I
might advise against pregnancy. After discussing the risks with
the patient, however, I would leave the decision to her.
Questions and answers
DR. NIcOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center Hospitals, Boston, Massachu-
setts): On the basis of the currently available data, you have
provided reasonable recommendations for the management of
diffuse proliferative lupus nephritis. What are your recommen-
dations for the treatment of the focal proliferative and the
membranous forms of the disease?
DR. STEINBERG: I don't know the best treatment for either of
those. We have to remember, however, that the biopsy picture
can change. The most recent published view is that the his-
tologic findings change in approximately 50% of lupus patients
subjected to another biopsy [70]. We don't find that membra-
nous disease is quite as benign as the initial studies suggested.
A substantial minority of patients with membranous disease
develop renal failure. Patients with focal proliferative nephritis
also can progress to diffuse disease. If re-biopsy shows progres-
sion to membranoproliferative or diffuse proliferative disease, I
treat these patients accordingly. For patients who do not
progress, I don't think we have the information that can tell us
how best to treat them.
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newton- Wellesley Hospital, Newton, Massachusetts): Is there
a relationship between serologic abnormalities, especially anti-
DNA antibodies, and biopsy findings in patients with lupus
nephritis?
DR. STEINBERG: Anti-DNA antibodies are associated with
renal disease in patients with lupus. However, if you investigate
anti-DNA antibodies in all lupus patients who have renal
disease, you will find that the patients with the highest anti-
DNA antibody titers often respond best to treatment (personal
unpublished data). Among the patients with renal disease, it is
the ones with low to intermediate amounts of anti-DNA anti-
bodies who are sometimes most refractory to treatment. Many
papers suggest that because the findings on a second biopsy
correlate with the results of serologic tests, one can follow the
patient's course by repeating the serologic tests and not repeat-
ing the biopsy. Our own experience does not coincide with
those results uniformly. Many patients with high anti-DNA
titers with or without slightly low complement levels go for
years without developing active renal disease or functional
deterioration. I would say that we are not smart enough to
prognosticate accurately from the serologic tests.
DR. HARRINGTON: What are the technical details of your
protocol for intravenous cyclophosphamide administration?
DR. STEINBERG: Cyclophosphamide can be administered in
as short a time as 15 to 30 minutes or as long a time as several
hours; the exact rate of flow doesn't make much difference.
What is important is the volume of fluid given over the next 24
hours. We give 3 to 4 liters/M2 of fluid over the 24 hours after
the patient receives the intravenous cyclophosphamide.
DR. ANDREW S. LEVEY (Division of Nephrology, NEMCH):
Do you adjust the dose of cyclophosphamide for the level of
renal function?
DR. STEINBERG: Both unmetabolized cyclophosphamide and
its metabolites are cleared primarily by the kidney. As a result,
one might anticipate that in a patient with substantially impaired
renal function, a standard dose of cyclophosphamide would
lead to greater immunosuppressive and leukopenic effects. In
practice, we do not adjust the dose until the glomerular filtration
rate is decreased to less than 20 to 25 ml per minute. In patients
with a serum creatinine of 5.0 mgldl or higher, we sometimes
start with a slightly lower dose than in those with lesser
elevations of serum creatinine.
DR. MADIAs: Should the extent of acute, lupus-induced,
interstitial renal disease influence the choice of therapy?
DR. STEINBERG: The randomization in our trials is based only
on the glomerular picture; thus the presence of interstitial
disease does not affect our management. There is no question,
however, that patients with extensive interstitial disease often
have a greater propensity to progress to renal failure than do
patients with only glomerular disease. We even have seen
occasional patients, as have been reported in the literature, who
have only interstitial disease. In my experience, some of those
patients do respond to cyclophosphamide. Most of the time,
patients have a mixed picture of glomerular disease and inter-
stitial inflammation. In our studies, the interstitial disease is
ameliorated by cyclophosphamide.
DR. MICHAEL P. MADAIO (Division of Nephrology,
NEMCH): Have the NIH studies on the treatment of lupus
nephritis stratified patients according to biopsy classification
and clinical characteristics?
DR. STEINBERG: Most of the papers published from our group
have randomized patients according to two simple criteria, the
presence of lupus and the presence of lupus renal disease of
defined severity. The second criterion has several features: the
patient has to have at least 1 g/day of proteinuria, at least 10 red
cells/high-power field, and red cell casts. Patients are excluded
from our studies if they have a creatinine clearance consistently
below 20 mllmin. Otherwise patients merely have to have
diffuse glomerular inflammatory disease. Our current study
includes three levels of stratification. Moreover, all groups have
more severe disease, on balance, than have those included
previously. The stratification study is still in progress, and we
have no information from it. Retrospective analysis of the
different groups revealed no significant differences among them
with regard to severity of inflammatory disease or renal func-
tion even though they were not prospectively stratified. Retro-
spective stratification suggested that patients with mild glomer-
ular inflammation, normal serum creatinine, and no scarring did
well regardless of therapy. Those with normal to slightly
782 Nephrology Forum
elevated creatinine levels and minimal scarring did well with an
immunosuppressive agent (azathioprine or eyelophosphamide)
added to the steroids. Patients with advanced disease (elevated
creatinine and substantial scarring) responded to none of the
oral regimens very well. Unfortunately, the number of patients
in each subgroup was small.
Da. ILONA SZER (Division of Pediatric Rheumatology.
NEMCH): How do you treat extrarenal exacerbations in pa-
tients with lupus nephritis? Do extrarenal manifestations re-
spond to cyclophosphamide?
DR. STEINBERG: Cyclophosphamide is not a good antiinflam-
matory drug for extrarenal disease. A patient with fever,
pleurisy, pericarditis, and rash will respond much better to 10 or
15 mg daily of prednisone than to cyclophosphamide alone, A
small study did suggest that patients with SLE and extrarenal
disease did not respond to cyclophosphamide without steroids
[1411. The one possible exception to that generalization is
central nervous system lupus, which, in a few patients, has
responded to cyclophosphamide given in bolus injections with-
out steroids. By and large, cyclophosphamide is not the optimal
treatment for acute, symptomatic extrarenal lupus. In patients
with extrarenal lupus who are receiving eyclophosphamide for
their renal disease in concert with low doses of steroids,
however, cyclophosphamide appears to exert a beneficial effect
on the extrarenal disease, We observed this synergy of steroids
and cyclophosphamide in murine [139, 148, 149] and in human
lupus nephritis [151, 1521. Few patients treated with cyclophos-
phamide and corticosteroids experience extrarenal flares.
DR. DAVID CAHAN (Chief Division of lVephrology, Faulkner
Hospital, Boston): What would you advise a woman whose
nephritis previously had responded to steroids, or to steroids
and azathioprine, who is now experiencing an exacerbation of
renal disease and who wishes to become pregnant?
DR. STEINBERG: I tell the patient that taking cyclophos-
phamide involves a substantial risk that she will not be able to
become pregnant, but that she will have a better chance of not
developing end-stage renal disease. She would have to decide
which alternative is best for her.
The patient's previous responses to a non-cyclophospha-
mide-containing regimen is irrelevant. In fact, the more lupus
renal flares, the greater the probability of developing end-stage
renal disease the next time. Three flares of lupus nephritis, each
with substantial deterioration in renal function, usually lead to
dialysis within the next several years. Because she responded
to steroids the first time, and to steroids and azathioprine the
second time, does not mean that she will respond to those
therapies the third time. Quite the contrary, she would be less
likely to respond, and would be unlikely to respond to anything
but boluses of cyclophosphamide the third time.
DR. LEVEY: I have several questions that relate to the design
and interpretation of the NIH studies: (I) Were patients ex-
cluded from your study on the basis of severity of renal or
extrarenal manifestations of lupus? If so, what were the criteria
for exclusion, and how many patients were excluded? (2) Were
the patients who were treated with prednisone alone treated
concurrently with the patients who received intermittent intra-
venous cyclophosphamide? (3) What was the duration and
treatment of lupus nephritis prior to entry into the study? Are
your treatment recommendations intended for patients at the
time of initial presentation, or only after initial stabilization
using other treatments, such as high-dose prednisone? (4) The
survival curves you showed for prednisone alone and for
intermittent intravenous cyclophosphamide appear to diverge
at approximately 5 years of followup. At that time, however,
only approximately 10 patients in each group are at risk.
Although the cures differ significantly on a statistical basis, do
you feel comfortable in recommending this new therapy based
on a study of so few patients?
DR. STEINBERG: Let me answer your questions sequentially.
(1) The protocol called for exclusion of patients whose extrare-
nal lupus could not be controlled by prednisone, 0.5 mg/kg/day,
plus nonsteroidal antiinflammatory drugs. A few patients, fewer
than 5%, were excluded on this basis. Among the small group
that initially was excluded, some were treated with higher doses
of prednisone, and later included when the prednisone was
tapered and glomerulonephritis persisted.
(2) Yes. The data I showed (Fig. 1) are the same for the pred-
nisone group that we treated concurrently; every patient treated
with IV. cyclophosphamide was treated as part of a random-
ized trial in which there was a steroids-only group. The curves
are identical for the steroids-only patients treated concurrently
with those treated with intravenous cyclophosphamide.
(3) The duration of lupus nephritis prior to the patients' entry
into the study varied from less than I month to greater than 10
years but averaged about 9 months. My comments today are my
own opinions plus data from randomized trials. I hope that
these comments are not taken as recommendations; what I do
recommend is that all patients with lupus nephritis be entered
into newer and better randomized trials. My principal message
is that although we have gathered a few observations over the
last 15 years, we still know much less than we should; we must
continue to perform trials that will improve our ability to
optimally care for our patients. This is a nationwide responsi-
bility, not the province of a few.
(4)1 agree that the groups contain relatively few patients and
that inadequate numbers have been followed for too short a
time. However, these are the best data available, and they help
guide us to perform better studies and to further improve our
patient care. As I said, these data are not meant to be recom-
mendations.
DR. MADAJO: How urgent is it that we begin giving cyclo-
phosphamide to patients at the time of their initial bout of acute
lupus nephritis?
DR. STEINBERG: I wish I knew the answer. My opinion is that
early vigorous treatment is the most likely method of eradicat-
ing the process and inducing a remission with normal renal
function. Because the kidney has substantial reserve, some
delay probably does not compromise the long-term outlook
greatly, but a substantial delay might. We need to study the
risks and benefits of vigorous initial therapy and to compare the
outcome with delays in therapy.
DR. MADAJO: How long should treatment with intravenous
cyclophosphamide boluses continue? More specifically, how
long were patients treated in the NIH study, and what was the
criterion for stopping therapy?
Da. STEINnERG: Our patients were treated for 5 years. If the
patients were in remission at that time and had been so for 6
months, the drug was stopped. I have the impression that some
patients need many years of bolus therapy to prevent functional
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deterioration, whereas others might require less, but we know
little about which patients to treat in this fashion.
DR. MADIAS: What is your view of the role of plasmapheresis
in the management of lupus nephritis?
DR. STEINBERG: I know of only two randomized trials of
plasmapheresis in patients with systemic lupus. One report
from the NIH of patients without renal disease showed little
benefit [157], but this study was performed in patients in whom
one might not expect much benefit. The second study, which I
believe is only available in abstract form, compared cyclophos-
phamide and plasmapheresis to cyclophosphamide, and sug-
gested only adjunctive benefit of apheresis [159].
DR. LEVEY: We currently are participating in a multicenter
trial of plasmapheresis in severe lupus nephritis. The Lupus
Nephritis Collaborative Study Group, under the direction of Dr.
Edmund Lewis, comprises 14 clinical centers and is funded by
the National Institutes of Health. Thus far approximately 90
patients with severe, diffuse proliferative nephritis have been
enrolled into a randomized study comparing short-term, high-
dose steroid therapy (prednisone, 50 to 60 mg/day for 2 months)
and short-term, low-dose cyclophosphamide (1 to 2 mg/kg/day
for 2 months) with the identical regimen also employing plas-
mapheresis (one plasma volume exchange) 3 times weekly for 4
weeks. Thereafter, patients are maintained on low-dose, alter-
nate-day prednisone; for subsequent renal flares, the original
treatment is repeated. To my knowledge, this study represents
the largest controlled study comparing only two forms of
therapy for lupus nephritis, and it should definitively answer the
question of the usefulness of plasmapheresis for severe
nephritis. As in your studies, our progress has been hampered
by a limited enrollment of patients. The study is still in
progress.
Da. HARRINGTON: Would you comment on the patients with
acute lupus nephritis who require dialysis in addition to other
treatment, but who subsequently regain their renal function?
DR. STEINBERG: Some patients with acute, active lupus
nephritis progress to the point of requiring dialysis but, with
treatment, they may subsequently no longer require dialysis. I
think the critical factor is the rate of change in renal function. If
someone who becomes acutely ill with lupus nephritis previ-
ously had a serum creatinine of less than 2 mgldl, we can
reasonably hope that therapy will produce sufficient renal
recovery to allow the patient to stay off dialysis for an extended
period, and perhaps indefinitely. Just because a patient with
lupus nephritis starts dialysis doesn't mean that dialysis will be
a permanent form of therapy. If the patient has had a slowly
progressive loss of renal function despite therapy and, for
example, had a serum creatinine of 4.0 mgldl two years ago and
6.0 mgldl one year ago, the likelihood of that patient responding
to therapy well enough to come off dialysis following an acute
flare is very small.
DR. PAUL ROMAIN (Division of Rheumatology, NEMCJI):
Have you identified any clinical or laboratory features other
than the "chronicity index" (renal scarring) that predict how
well a patient will respond to cyclophosphamide?
DR. STEINBERG: Patients who respond poorly to cyclophos-
phamide also respond poorly to the other commonly used
drugs. These patients have the highest ratios of irreversible to
reversible changes. In a patient under treatment who is fol-
lowed for several years, I believe that the serum creatinine is
almost as good an indicator as is the "chronicity index." The
chronicity index simply is a measurement of the extent of
scarring, including interstitial fibrosis and glomerular sclerosis.
The difilcult cases are those with substantial disease activity
and substantial scarring. With vigorous therapy, the renal
function of some of these patients may stabilize and the patients
may escape dialysis.
DR. ROMAIN: What is your approach to the treatment of
patients both with and without lupus nephntis during pregnancy
as well as during labor and postpartum?
DR. STEINBERG: For lupus patients without nephritis, I
suggest using steroid doses during labor and delivery compara-
ble to dosages used during surgery in these patients, and then
maintaining the steroids at a dose of about 20 to 30 mg/day of
prednisone for about 4 to 6 weeks after delivery before tapering
the drug. If the patient had not received steroids prior to
delivery or is taking 5 or 10 mg every other day, I might
decrease the steroid dose even more rapidly. In my experience,
this type of therapy in pregnant patients who have not had renal
disease, and in several who have had renal disease, seems to
have been effective. None of our patients have had postpartum
exacerbations.
In regard to the treatment of patients with SLE who have had
nephritis and who have been in remission on minimal therapy
for several years before they became pregnant, I do not
increase the prednisone dose on the basis of the pregnancy
alone. We advise patients with active lupus, especially those
with active renal disease, not to conceive. If a patient with
active lupus nephritis becomes pregnant or if a patient develops
active lupus nephritis while pregnant, the approach depends
both on the patient's medical condition and desires. If one
concentrates on the health of the mother, vigorous therapy will
be beneficial but could harm the fetus. Six-mercaptopurine and
high doses of corticosteroids may be the best treatment in a
pregnant woman who unequivocally wants to keep the fetus;
however, studies are needed to test that idea. Although only
empiric evidence is available, I believe that an abortion can be
therapeutic, not only saving the woman's kidneys, but possibly
her life, in some pregnant patients with severe lupus nephritis
and with hypertension that is difficult to control. Failure to
abort early often leads to a stillbirth later and to an unusually
difficult illness that can lead to permanent loss of renal function.
DR. LEVEY: What are the indications for renal biopsy in
patients with lupus?
DR. STEINBERG: If you don't know how to treat the patient,
and if more information will help you decide on therapy, renal
biopsy is indicated. If you know that you are going treat with 80
mg/day of prednisone, or prednisone and azathioprine, or
intravenous cyclophosphamide, then there is no reason to do a
biopsy. I believe it is inappropriate to perform a renal biopsy for
diagnostic purposes in a patient with lupus, that is, to confirm or
demonstrate that the patient has lupus nephritis. However, if
there is a real question as to whether the renal disease is due to
lupus, then I think it is appropriate to do a biopsy for diagnostic
purposes.
Several kinds of patients have lupus and urinary abnormali-
ties; one kind has normal urinary findings or such mild alter-
ations that a biopsy is unlikely to provide information that
would dictate vigorous therapy. The second type is patients
with very abnormal urinalyses, and who have elevated serum
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ereatinine levels; these people don't need a biopsy either,
because vigorous therapy is indicated no matter what the
biopsy shows. The people who should be biopsied are the ones
for whom you need to determine the least toxic but most
effective regimen. A biopsy is like any other test: the potential
risks must be justified by the need for obtaining valuable
information.
DR. HARRINGTON: Do you have any preliminary findings on
the efficacy of intravenous cyclophosphamide versus that of
intravenous methylprednisolone in the treatment of lupus
nephritis?
DR. STEINBERG: A randomized trial of intravenous eyelophos-
phamide versus intravenous steroids is currently underway at
the NIH, but no data are yet available.
DR. ROMAIN: Given the experience with monoelonal antibod-
ies in murine autoimmunity and in human renal allograft rejec-
tion, do you think the potential exists for therapy with mono-
elonal antibodies in patients with lupus nephritis?
DR. STEINBERG: I am encouraged by the precedents for the
use of monoelonal antibodies in lupus patients. If B-cell subsets
are largely responsible for autoantibody production, monoclo-
nal antibodies against such a subset might be effective and
nontoxie in patients with early disease. Alternatively, one might
use a pan-B cell antibody to prevent activation of many B cells,
including those that lead to autoantibodies, and to titrate B-cell
function so as to reduce pathogenetic antibody production to an
effective level without allowing unreasonable predisposition to
infection. It is conceivable that antiidiotype therapy might be
useful if one could identify idiotypes that are antibodies partic-
ularly injurious to the kidney, but I am doubtful that it will be a
good therapy. Anti-T-cell antibodies might be useful in periods
of remission but are unlikely to be useful in active disease. My
personal bias is that titrating down B-cell activation is the most
promising use of monoclonal antibodies in the near future.
DR. OLEI-I PANKEWvCZ (Fellow, Division of Nephrology,
NEMCI-I): What is the mechanism of action of cyclophos-
phamide in lupus nephritis?
DR. STEINBERG: Cyclophosphamide prevents inflammatory
cells from residing in the kidneys, and it reduces antibody
production, including autoantibodies. I do not know which of
the several possible mechanisms is largely responsible for
benefit.
DR. MAmAs: You emphasized the importance of early and
aggressive treatment of hypertension as a means of preserving
renal function. Does this recommendation represent extrapola-
tion from other renal diseases, such as diabetic nephropathy, or
experience in patients with lupus nephritis?
DR. STEINBERG: In experimental animals, mild immune-
complex disease does little damage in the kidney. Mild hyper-
tension alone does little damage. Together, however, they
induce rapidly progressive renal failure. In patients with lupus
nephritis and diffuse proliferative or membranoproliferative
disease, vigorous control of hypertension markedly retards the
deterioration of renal function. I believe th. many of our
patients develop end-stage renal disease much more slowly
partly because their blood pressures arc tightly controlled.
Reprint requests to Dr. A. Steinberg, Building 10, Room 9N-218,
National Institutes of Health, Bethesda, Maryland 20892, USA
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